tiprankstipranks
Advertisement
Advertisement

MLTX Stock Latest News

Buy Rating on MoonLake: Sonelokimab’s Differentiated IL‑17 Profile and Late‑Stage HS Opportunity Support $40 Target
RatingsBuy Rating on MoonLake: Sonelokimab’s Differentiated IL‑17 Profile and Late‑Stage HS Opportunity Support $40 Target
23d ago
MLTX
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics
PremiumRatings
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics
24d ago
MLTX
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value
PremiumRatings
MoonLake Buy Rating: Clear HS Approval Path, Priority Review Upside, and Underappreciated Multi-Indication Value
1M ago
MLTX
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial
PremiumThe Fly
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial
1M ago
MLTX
MoonLake Immunotherapeutics management to meet with BTIG
PremiumThe Fly
MoonLake Immunotherapeutics management to meet with BTIG
1M ago
MLTX
MoonLake upgraded to Outperform from Underperform at Wolfe Research
PremiumThe FlyMoonLake upgraded to Outperform from Underperform at Wolfe Research
2M ago
MLTX
Micron downgraded, Five Below upgraded: Wall Street’s top analyst calls
Premium
The Fly
Micron downgraded, Five Below upgraded: Wall Street’s top analyst calls
2M ago
MU
ADP
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
Premium
The Fly
MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn
2M ago
MLTX
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
PremiumRatings
MoonLake Immunotherapeutics: Sonelokimab’s Differentiated IL‑17A/F Profile and Multibillion-Dollar Potential Underpin Buy Rating Despite HS Trial Concerns
2M ago
MLTX
MoonLake price target raised to $70 from $45 at Clear Street
PremiumThe Fly
MoonLake price target raised to $70 from $45 at Clear Street
2M ago
MLTX
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright
PremiumThe Fly
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright
2M ago
MLTX
MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs
PremiumThe Fly
MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs
2M ago
MLTX
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
PremiumThe FlyMoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer
2M ago
MLTX
Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
Premium
Ratings
Sonelokimab: Strong HS and AxSpA Data, Clear Regulatory Path Support Best‑in‑Class Potential and Buy Rating
2M ago
MLTX
MoonLake Highlights Positive S-OLARIS Data and Investor Day
Premium
Company Announcements
MoonLake Highlights Positive S-OLARIS Data and Investor Day
2M ago
8K
MLTX
MoonLake announces results from Phase 2 trial of Sonelokimab
PremiumThe Fly
MoonLake announces results from Phase 2 trial of Sonelokimab
2M ago
MLTX
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target
PremiumRatings
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target
3M ago
MLTX
MoonLake announces FDA granted Fast Track designation for sonelokimab
PremiumThe Fly
MoonLake announces FDA granted Fast Track designation for sonelokimab
3M ago
MLTX
Midday Fly By: TSMC reports Q4 beat, Goldman Sachs raises dividend
PremiumThe Fly
Midday Fly By: TSMC reports Q4 beat, Goldman Sachs raises dividend
4M ago
BA
GS
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
PremiumThe FlyMoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
4M ago
MLTX
MoonLake price target raised to $32 from $26 at H.C. Wainwright
Premium
The Fly
MoonLake price target raised to $32 from $26 at H.C. Wainwright
4M ago
MLTX
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG
Premium
The Fly
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG
4M ago
MLTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >